Cagrilintide/semaglutide
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Novo Nordisk · Phase 3 · Completed · Enrollment 331
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| CagriSema 2.4 mg/2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
Not shown
- CagriSema 2.4 mg/2.4 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported